Hence, combination therapies that include JAK2/STAT3 and CSC-specific targeted agents and a non-CSC-targeted agent such as chemotherapy, may be a more effective approach for the treatment of ovarian cancer [25–27]. Here, STAT3 is linked to ovarian cancer.